Key result
High TMTV and poor interim PET response predict ~9-fold greater risk of early progression or death.
Why the study?
Because outcomes were unaffected by interim PET-based treatment changes in the PETAL trial, investigators evaluated the prognostic value of baseline total metabolic tumor volume and interim PET response in T-cell lymphoma.
Do baseline TMTV and interim PET response predict survival in patients with T-cell lymphoma?
Population
76 patients with T-cell lymphoma
Comparison
Baseline TMTV and interim PET response metrics
Design
Subgroup analysis of a prospective randomized trial
Authors
Loading...
May flag early failure risk in ALK-negative T-cell lymphoma; hypothesis-generating for PET-adapted trials.
RCT (n=76)
Do baseline TMTV and interim PET response predict survival in patients with T-cell lymphoma?
Hazard Ratio: 9.031 (95% CI 3.651–22.336)
Baseline TMTV and interim PET response are strong predictors of survival in ALK-negative T-cell lymphoma, identifying high-risk patients who may benefit from early alternative therapies.
Rekowski et al. (2020) conducted an RCT in T-cell lymphoma (n=76). High baseline total metabolic tumor volume (TMTV) and poor interim PET (iPET) response vs. Low TMTV and good iPET response was evaluated on Progression or death within the first year (HR 9.031, 95% CI 3.651-22.336). High baseline TMTV and poor interim PET response predicted progression or death within the first year in ALK-negative T-cell lymphoma (HR 9.031; 95% CI 3.651-22.336).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: